LSL Pharma Group Inc.
LSL.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 70.33% | 56.19% | 51.30% | 57.01% | 102.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 70.33% | 56.19% | 51.30% | 57.01% | 102.29% |
| Cost of Revenue | 92.10% | 50.64% | 13.22% | 35.37% | 94.22% |
| Gross Profit | 32.70% | 70.79% | 1,330.75% | 151.99% | 117.92% |
| SG&A Expenses | 3.56% | 66.62% | 29.78% | 54.04% | 32.64% |
| Depreciation & Amortization | -- | -- | 1.75% | 4.47% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.81% | 54.52% | 17.52% | 39.63% | 58.55% |
| Operating Income | 311.66% | 93.37% | 125.73% | 133.58% | 78.51% |
| Income Before Tax | 25.43% | 8.76% | 448.12% | 50.18% | 51.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 25.43% | 8.76% | 444.30% | 50.18% | 51.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 25.43% | 8.76% | 444.30% | 50.18% | 51.15% |
| EBIT | 311.66% | 93.37% | 125.73% | 133.58% | 78.51% |
| EBITDA | 390.07% | 75.35% | 158.65% | 355.65% | 155.63% |
| EPS Basic | 33.33% | 36.00% | 345.13% | 63.77% | 61.70% |
| Normalized Basic EPS | 37.50% | 33.33% | 82.67% | 57.89% | 59.32% |
| EPS Diluted | 33.33% | 36.00% | 273.15% | 66.67% | 61.70% |
| Normalized Diluted EPS | 37.50% | 33.33% | 82.67% | 57.89% | 59.32% |
| Average Basic Shares Outstanding | 9.23% | 36.60% | 40.64% | 39.60% | 28.31% |
| Average Diluted Shares Outstanding | 9.10% | 36.60% | 40.64% | 39.84% | 28.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |